Deep learning platform for fully automatic segmentation and phenotyping of coronary intravascular ultrasound (IVUS) pullbacks, packaged with a desktop GUI and CLI. A convolutional encoder-decoder network delineates the internal (lumen) and external elastic lamina borders on each cross-sectional IVUS frame; downstream rule-based analysis derives lumen area, plaque area, plaque burden, automatically flags lesions with plaque burden exceeding 40%, and reports minimum lumen area and maximum plaque burden along the pullback. Also supports end-diastolic gating and manual contour editing. Trained on 305 clinical IVUS pullbacks (270 train / 35 validation) from Philips and Boston Scientific catheters at Emory University; downstream evaluations have applied DeepIVUS to tasks such as automated detection of stent underexpansion.

nnU-Net-based segmentation network that detects and delineates stenotic lesions directly from X-ray coronary angiography frames, developed for the ARCADE (MICCAI 2023) stenosis-detection challenge. A companion model (YOLO-Angio, same team) handles vessel-tree segmentation; StenUNet focuses specifically on pixel-wise localization of stenotic regions. Placed 3rd overall among ARCADE challenge entrants with an F1 score of 0.5348 on the hold-out test set, within 0.0005 of the 2nd-place team.

U-Net-variant segmentation model that identifies and quantifies coronary artery calcium (CAC) directly from routine non-gated, non-contrast chest CT scans -- the kind ordered for lung-cancer screening or unrelated indications rather than a dedicated cardiac scan -- so that the tens of millions of such scans performed annually can be opportunistically screened for cardiovascular risk without any extra imaging. Predicted calcium masks are combined with the CT's Hounsfield units to compute an Agatston-equivalent score. Trained on 446 expert-segmented scans from 98 medical centers across the U.S. Department of Veterans Affairs national health system (capturing substantial heterogeneity in scanners and protocols) and benchmarked against 795 patients with a paired same-year gated CAC study: nongated AI-CAC differentiates zero-vs-nonzero and <100-vs->=100 Agatston categories with 89.4% (F1 0.93) and 87.3% (F1 0.89) accuracy respectively, and its score stratifies 10-year all-cause mortality (CAC 0 vs. >400: 25.4% vs. 60.2%, hazard ratio 3.49) and composite stroke/MI/death risk (33.5% vs. 63.8%, hazard ratio 3.00). In a simulated opportunistic-screening run across 8,052 low-dose CT scans, cardiologists confirmed 99.2% of patients flagged with AI-CAC >400 would benefit from lipid-lowering therapy. Code and trained model weights are both public under an MIT license.